(Q40477521)

20 September 2017

title

In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. (English)

1 reference

20 September 2017

0 references

1 reference

Hubert R Kübler

1

1 reference

20 September 2017

Heiner van Randenborgh

2

1 reference

20 September 2017

Uwe Treiber

3

1 reference

20 September 2017

Sebastian Wutzler

4

1 reference

20 September 2017

Carolus Battistel

5

1 reference

20 September 2017

Antonie Lehmer

6

1 reference

20 September 2017

Stefan Wagenpfeil

7

1 reference

20 September 2017

Rudolf Hartung

8

1 reference

20 September 2017

Roger Paul

9

1 reference

20 September 2017

publication date

1 June 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

63

1 reference

20 September 2017

issue

4

1 reference

20 September 2017

page(s)

385-394

1 reference

Management of cancer of the prostate

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20201

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20201

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20201

An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20201

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20201

Platelet-derived growth factor receptors: a therapeutic target in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20201

Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20201

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20201

Imatinib: a selective tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20201

A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20201

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20201

21 January 2018

Identifiers

DOI

10.1002/PROS.20201

1 reference

20 September 2017

1 reference